All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

home / precision-medicine / expanding-options-for-relapsed-refractory-her2-metastatic-breast-cancer

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Treatment Options in HER2+ Metastatic Breast Cancer

EP. 1: Treatment Options in HER2+ Metastatic Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Trastuzumab Emtansine in HER2+ Breast Cancer

EP. 2: Trastuzumab Emtansine in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Options in Breast Cancer After HER2+ Targeted Therapy

EP. 3: Options in Breast Cancer After HER2+ Targeted Therapy

Targeted Oncology
July 7th 2020

Watch

Trastuzumab Deruxtecan in HER2+ Breast Cancer

EP. 4: Trastuzumab Deruxtecan in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Neratinib + Capecitabine in HER2+ Breast Cancer

EP. 5: Neratinib + Capecitabine in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Understanding HER2CLIMB Clinical Trial

EP. 6: Understanding HER2CLIMB Clinical Trial

Targeted Oncology
July 7th 2020

Watch

Toxicity Management When Using HER2CLIMB Regimen

EP. 7: Toxicity Management When Using HER2CLIMB Regimen

Targeted Oncology
July 7th 2020

Watch

Next-Generation Sequencing in HER2+ Breast Cancer

EP. 8: Next-Generation Sequencing in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Newly Approved Agents for HER2+ Breast Cancer

EP. 9: Newly Approved Agents for HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.